Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Kisqali by Quarter
Kisqali — Number of Countries with Reimbursement Approval for eBC Indication
Novartis Kisqali: 43 in Q3 2026.
Latest, Q3 2026
43
Period ended Sep 30, 2026
Change on a year earlier
–
History
4 quarters
Since Q4 2025
Sources
4
Documents cited below
Where the Q3 2026 figure comes from
“| approved in 84 countries and reimbursed in 43”
Source: Novartis Official IR / Sustainability Report — q3-2026-investor-presentation.pdf ↗
Reported in Quarterly Investor Presentations.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Kisqali — Number of Countries with Reimbursement Approval for eBC Indication | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 43 | – | Novartis Official IR / Sustainability Report — q3-2026-investor-presentation.pdf ↗ |
| Q2 2026 | Jun 30, 2026 | 42 | – | Novartis Official IR / Sustainability Report — q2-2026-investor-presentation.pdf ↗ |
| Q1 2026 | Mar 31, 2026 | 40 | – | Novartis Official IR / Sustainability Report — q1-2026-investor-presentation.pdf ↗ |
| Q4 2025 | Dec 31, 2025 | 35 | – | Novartis Official IR / Sustainability Report — q4-2025-investor-presentation.pdf ↗ |
Cite this data
StockData. (2026). Novartis Kisqali, quarterly Q4 2025–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/rx-kisqali-ebc-reimbursed-countries
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.